Stocks to Buy: Shares of this 'super compounder' can rise another 30%, UBS predicts
According to UBS, Max Healthcare is well-positioned to deliver both capacity expansion and earnings growth. The brokerage said that a CGHS price increase would provide a meaningful tailwind for the company.
According to UBS, Max Healthcare is well-positioned to deliver both capacity expansion and earnings growth. The brokerage said that a CGHS price increase would provide a meaningful tailwind for the company.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
